



ASCO Meeting 2024 Participation

2024 Young Investigator Award Recipients

Rebecca Forman, MD

Yiduo Hu, MD, PhD

Tendai Kwaramba, MD, MSc

ASCO Education Scholar

Thejal Srikumar, MD

Friday, May 31

Workshop

In-Person Workshop: Genomics 101 for Oncologists

Medical Oncologist Perspective May 31; 1:00 – 5:00 PM CDT

Presenter: Michael E. Hurwitz, MD, PhD

Location: S105ab

Saturday, June 1

Oral Abstract

Genitourinary Cancer—Kidney and Bladder

Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).

June 1; 8:42 – 8:48AM CDT Presenter: Soki Kashima

Location: S100bc | Abstract 4515

Poster Session

Developmental Therapeutics—Immunotherapy

SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy.

June 1; 9:00 – 12:00PM CDT Presenter: Philippos Costa

Location: Hall A | Abstract 2578 | Poster Bd 57

Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Comprehensive characterization of ERBB2 genomic alterations in lung cancer. June 1; 9:00 – 12:00PM CDT Presenter: Talal El Zarif

Location: Hall A | Abstract 3148 | Poster Bd 293

Poster Session Sarcoma

Sorafenib treatment duration in desmoid tumors.

June 1; 1:30 – 4:30PM CDT Presenter: Philippos Costa

Location: Hall A | Abstract 11585 | Poster Bd 511

Poster Session

Central Nervous System Tumors

Real-world use of a CSF circulating tumor cell assay in the diagnosis and management of leptomeningeal metastasis.

Presenter: Nicholas Blondin June 1; 9:00 – 12:00PM CDT

Location: Hall A | Abstract: 2029 | Poster Bd 328

Poster Session

Developmental Therapeutics—Immunotherapy

Development of an mRNA therapeutic vaccine for virally driven Merkel cell carcinoma.

June 1; 9:00 – 12:00PM CDT Presenter: Alexander Frey

Location: Hall A | Abstract 2637 | Poster Bd 116

Poster Session

Developmental Therapeutics—Immunotherapy

A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.

June 1; 9:00 – 12:00PM CDT Senior Author: Barbara Burtness

Location: Hall A | Abstract TPS2701 | Poster Bd 164a

Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer.

June 1; 9:00 – 12:00 PM CDT Senior Author: Patricia LoRusso

Location: Hall A | Abstract TPS3183 | Poster Bd 316a

Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Comprehensive characterization of ERBB2 genomic alterations in lung cancer.

June 1; 9:00 – 12:00PM CDT Presenter: Talal El Zarif

Location: Hall A | Abstract 3148 | Poster Bd 293

Poster Session

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology <u>HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory</u> metastatic solid tumors.

June 1; 9:00 – 12:00PM CDT Presenter: Aarti Bhatia

Location: Hall A | Abstract TPS3164 | Poster Bd 307a

Education Session

Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates
Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates

June 1; 1:15 – 2:30PM CDT Presenter: Patricia LoRusso

Location: Hall D1

Education Session

Tackling the Tough Stuff: Managing Challenging Symptoms and Patient Conversations Around Goals of

Care

Primary Palliative Care Skills: How to Integrate Into Your Oncology Practice

June 1; 1:15 – 1:30PM CDT Presenter: Jennifer Kapo

Location: E450a

Education Session

State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers

Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches

June 1; 1:30 – 1:45 PM CDT Presenter: David Braun Location: Hall D2

Poster Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).

June 1; 1:30 – 4:30PM CDT Presenter: Jacquelyne Gaddy

Location: Hall A | Abstract 4138 | Poster Bd 118

Poster Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.

June 1; 1:30 – 4:30PM CDT Presenter: Pamela Kunz

Location: Hall A | Abstract 4131 | Poster Bd 111

Poster Session

Melanoma/Skin Cancers

<u>Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker</u> for stratification for clinical trials.

June 1; 1:30 – 4:30PM CDT Presenter: Thazin Aung

Location: Hall A | Abstract 9567 | Poster Bd 351

Education Session

Advanced Lung Cancer: State-of-the-Art Approaches and Insights

Small Cell Lung Cancer
June 1; 3:00 – 3:15 PM CDT
Presenter: Anne C. Chiang

Location: S406

Oral Abstract

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

<u>A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2- breast cancer.</u>

June 1; 4:24 – 4:36PM CDT Presenter: Pat LoRusso

Location: Hall D1 | Abstract 3006 |

Education Session

Navigating the Complexities of Brain Metastases Management

June 1; 4:45 -6:00 PM CDT Chair: Sarah B. Goldberg, MD

Location: E450a

Education Session

Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?

June 1; 4:45 -5:00 PM CDT

Presenter: Sarah B. Goldberg, MD

Location: E45a

Sunday, June 2

Oral Abstract

Gastrointestinal Cancer—Colorectal and Anal

ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).

June 2; 10:24 – 10:36 AM CDT Senior Author: Michael Cecchini

Location: Arie Crown Theater | Abstract 3508

Poster Session

Genitourinary Cancer—Kidney and Bladder

Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).

June 2; 9:00 – 12:00PM CDT Senior Author: David Braun

Location: Hall A | Abstract 4546 | Poster Bd 241

Poster Session

Genitourinary Cancer—Kidney and Bladder

A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.

June 2; 9:00 – 12:00PM CDT Senior Author: Dan Petrylak

Location: Hall A | Abstract TPS4619 | Poster Bd 308a

Poster Session

Breast Cancer—Local/Regional/Adjuvant

Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer. article

June 2; 9:00 – 12:00PM CDT Presenter: Daniel O'Neil

Location: Hall A| Abstract 522| Poster Bd 114

Poster Session Breast Cancer

Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier derived individual-patient data meta-analysis.

June 2; 9:00 – 12:00PM CDT Senior Author: Maryam Lustberg

Location: Hall A | Abstract 1065 | Poster Bd 43

Poster Session

Head and Neck Cancer

Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study.

June 2; 9:00 – 12:00 PM CDT Senior Author: Joseph Kim

Location: Hall A | Abstract 6079 | Poster Bd 395

Poster Session

Breast Cancer

<u>Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.</u>

June 2; 9:00 – 12:00PM CDT Presenter: Nicole Odzer

Location: Hall A | Abstract 1104 | Poster Bd 82

Poster Session

Breast Cancer—Metastatic

Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).

June 2; 9:00 – 12:00PM CDT Presenter: Melissa Taylor

Location: Hall A | Abstract 1092 | Poster Bd 70

Poster Session

Breast Cancer—Local/Regional/Adjuvant

Correlation of hormone receptor positive HER2-negative/MammaPrint high-2 breast cancer with triple negative breast cancer: Results from gene expression data from the ISPY2 trial.

June 2; 9:00 – 12:00PM CDT Presenter: Alejandro Rios-Hoyo

Location: Hall A | Abstract 573 | Poster Bd 165

Case-Based Panel

Optimizing Treatment of Locally Advanced Non–Small Cell Lung Cancer: A Multimodal Approach in the Immunotherapy Era

Radiation Oncologist Perspective

June 2; 11:30 AM CDT

Presenter: Henry Soo-Min Park

Location: Hall D1

Clinical Science Symposium
Care Delivery and Quality Care

Navigating Global Cancer Care: Conflict, Access, and Delivery

June 2; 12:18 – 12:30 PM CDT Presenter: Daniel O'Neil Location: S100bc

Oral Abstract

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).

June 2; 4:30 – 6:00PM CDT Presenter: Ritujith Jayakrishnan Location: S406 | Abstract 8013

Monday, June 3

Oral Abstract

Genitourinary Cancer—Kidney and Bladder

Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.

June 3; 8:24 – 8:36AM CDT Presenter: Daniel Petrylak Location: Hall B1 | Abstract 4503

Poster Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)—naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.

June 3; 9:00 – 12:00PM CDT Presenter: Amer Zeidan

Location: Hall A | Abstract 6565 | Poster Bd 124

Poster Session

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge.

June 3; 9:00 – 12:00PM CDT Presenter: Amer Zeidan

Location: Hall H | Abstract 6566 | Poster Bd 125

Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)—targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).

June 3; 9:00 – 12:00PM CDT Presenter: Poy Theprungsirikul

Location: Hall A | Abstract 7549 | Poster Bd 186

Poster Session

Quality Care/Health Services Research

Oral cancer drug repositories: Challenges and solutions.

June 3; 9:00 – 12:00PM CDT Senior Author: Osama Abdelghany

Location: Hall A | Abstract 11063 | Poster Bd 258

Poster Session

Quality Care/Health Services Research

Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.

June 3; 9:00 – 12:00PM CDT Presenter: Laura Baum Location: Hall A | Abstract 447678 | Poster Bd 254

Poster Session

Quality Care/Health Services Research

Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis.

June 3; 9:00 – 12:00PM CDT Senior Author: Maureen Can

Location: Hall A | Abstract 11092 | Poster Bd 287

Poster Session

Hematologic Malignancies—Plasma Cell Dyscrasia

Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma.

June 3; 9:00 – 12:00PM CDT Presenter: Sabrina Browning

Location: Hall A | Abstract 7559 | Poster Bd 196

Oral Abstract

Medical Education and Professional Development

Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.

Presenter: Thejal Srikumar
June 3; 9:51 – 9:57AM CDT
Location: E450a | Abstract 9004

Oral Abstract

Genitourinary Cancer—Prostate, Testicular, and Penile

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

June 3; 1:27 – 1:33PM CDT Presenter: Daniel Petrylak Location: Hall B1| Abstract 5011

Poster Session

Symptom Science and Palliative Care

<u>Factors associated with sexual function and sexual satisfaction in young women with breast cancer.</u>

June 3; 1:30 – 4:30PM CDT Presenter: Ana Ferrigno Guajardo

Location: Abstract 12062 | Poster Bd 191

Poster Session

Lung Cancer

<u>Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC).</u>

June 3; 1:30 – 4:30PM CDT Senior Author: Roy Herbst

Location: Hall A | Abstract 8046 | Poster Bd 308

Poster Session

Prevention, Risk Reduction, and Genetics

Estimating risk for pancreatic cancer among 9.4 million veterans in care.

June 3; 1:30 – 4:30PM CDT Presenter: Louise Wang

Location: Hall A | Abstract 10544 | Poster Bd 71

Poster Session Lung Cancer

Lymph node metastasis prediction with non-small cell lung cancer histopathology imaging.

Presenter: Victor Lee June 3; 1:30 – 4:30PM CDT

Location: Hall A | Abstract 8063 | Poster Bd 325

Poster Session

Prevention, Risk Reduction, and Genetics

Associations between violence, distress, and cancer in transgender and non-transgender people.

June 3; 1:30 – 4:30PM CDT Presenter: Ash Alpert

Location: Abstract 10566 | Poster Bd 93

Poster Session

Prevention, Risk Reduction, and Genetics

Population attributable fraction of reproductive factors in triple negative breast cancer by race.

June 3; 1:30 - 4:30PM CDT

Presenter: Rachel Jaber Chehayeb

Location: Hall A | Abstract 10522 | Poster Bd 49

Poster Session

Symptom Science and Palliative Care

Neurofilament light chains: A biomarker for vincristine-related neuropathy.

June 3; 1:30 – 4:30PM CDT Senior Author: Maryam Lustberg

Location: Hall A | Abstract 12114 | Poster Bd 243

Poster Session

Prevention, Risk Reduction, and Genetics

Blood type as a risk factor for pancreatic ductal adenocarcinoma.

June 3; 1:30 – 4:30PM CDT Presenter: Navid Rahimi Larki

Location: Hall A | Abstract 10559 | Poster Bd 86

Poster Session

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.

June 3; 1:30 – 4:30PM CDT Presenter: Amin Nassar

Location: Hall A | Abstract 8106 | Poster Bd 368

Poster Session

Lung Cancer—Non-Small Cell Metastatic

Comparison of chemotherapy to chemo-immunotherapy as first-line treatment in patients with advanced large cell neuroendocrine carcinomas (LCNECs) of mixed histology: A multi-institutional international retrospective study.

June 3; 1:30 – 4:30PM CDT Presenter: Kelsey Matteson

Location: Hall A | Abstract 8602 | Poster Bd 466

Clinical Science Symposium

Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.

June 3; 3:12 – 3:24PM CDT Presenter: Barbara Burtness Location: E451 | Abstract 6009

Education Session

Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies Impact of Emerging Legislation on Cancer Care—A Hospital-Based Perspective

June 3; 3:15 – 3:30 PM CDT Presenter: Osama Abdelghany

Location: S102

Oral Abstract

Breast Cancer—Local/Regional/Adjuvant

<u>Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.</u>

June 3; 5:24 – 5:36PM CDT Presenter: Lajos Pusztai

Location: Hall B1 | Abstract 508

Tuesday, June 4

Oral Abstract Session
Head and Neck Cancer
Chair: Aarti K. Bhatia

June 4; 9:45 – 12:45PM CDT Location: S100a | Live Stream

Oral Abstract

Head and Neck Cancer

A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).

June 4; 10:57 – 11:09AM CDT Senior Author: Sarah Pai

Location: S100a | Abstract 6004

Publications Only

Publication Only

Central Nervous System Tumors

HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer.

Senior Author: Kurt Schalper Location: Abstract e14014

Publication Only

Care Delivery/Models of Care

<u>Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented</u>

minorities in cancer clinical trials.
Senior Author: Neal Fischbach
Location: Abstract e13586

Publication Only

Pediatric Oncology

Modeling response to alkylating chemotherapy in a syngeneic model of MMR-deficient glioma.

article

Senior Author: Deepti Bhatt Location: Abstract e22001

https://meetings.asco.org/abstracts-presentations/231055

Publication Only
Breast Cancer

Predicting peripheral neuropathy following neoadjuvant therapy in patients with breast cancer.

Senior Author: Maryam Lustberg Location: Abstract #e12639

Publication Only

Sarcoma

<u>Survival trends of soft tissue sarcomas and gastrointestinal stromal tumors from 1995 to 2019: A SEER</u> database analysis.

Senior Author: Philippos Costa Location: Abstract #e23528

Publication Only

Melanoma/Skin Cancers

<u>Causes of death and patterns of metastatic disease at the end of life for patients with advanced</u> melanoma in the immunotherapy era.

Author: Daniel Lee

Location: Abstract e21522

Publication Only

Symptom Science and Palliative Care

Impact of semaglutide and tirzepatide administration on weight in women with stage I-III breast cancer.

Author: Neal Fischbach Location: Abstract e24140

Publication Only

Care Delivery and Quality Care

Personalized risk assessment of new onset depression in long-term cancer survivors.

article

Author: Melissa Taylor Location: Abstract e13798

Publication Only

Medical Education and Professional Development

A medical school curriculum to foster the physician-patient relationship through narrative medicine.

<u>article</u>

Author: Johnathan Yao Location: Abstract e21015

Publication Only

Care Delivery/Models of Care

The unmet needs of women with metastatic breast cancer in Mexico: A qualitative study.

Author: Ana Ferrigno Guajardo Location: Abstract e13547

Publication Only
Lung Cancer

Real world outcomes of patients with small cell lung cancer (SCLC) presenting with brain metastasis at

diagnosis in a single institution health system.

Author: Julia Joseph

Location: Abstract: e20136